Drug - Tudorza Pressair [Forest Labratories, Inc.]
Therapeutic area - COPD
- Patient has a diagnosis of COPD AND
- Patient is greater than 18 years of age AND
- Patient has had an inadequate response or is intolerant to, Spiriva as documented in clinical progress notes
1 inhaler per month
TUDORZA PRESSAIR is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
MHCP Provider Call Center 651-431-2700 or 800-366-5411